Effectiveness of 8- or 12-weeks of ledipasvir and sofosbuvir in real-world treatment-naïve, genotype 1 hepatitis C infected patients-Reference-Cited by-同舟云学术

Effectiveness of 8- or 12-weeks of ledipasvir and sofosbuvir in real-world treatment-naïve, genotype 1 hepatitis C infected patients

Published:2017-07-10 Issue:5 Volume:46 Page:540-548
ISSN:0269-2813
Container-title:Alimentary Pharmacology & Therapeutics
language:en
Short-container-title:Aliment Pharmacol Ther

Author:

Curry M. P.¹^ORCID,Tapper E. B.²,Bacon B.³,Dieterich D.⁴,Flamm S. L.⁵,Guest L.⁶,Kowdley K. V.⁷,Lee Y.⁶,Milligan S.⁶,Tsai N.⁸,Younossi Z.⁹^ORCID,Afdhal N. H.¹

Affiliation:

1. Division of Gastroenterology and Hepatology; Department of Medicine; Beth Israel Deaconess Medical Center; Harvard Medical School; Boston MA USA

2. Division of Gastroenterology and Hepatology; University of Michigan; Ann Arbor MI USA

3. Division of Gastroenterology/ Hepatology; Saint Louis University School of Medicine; Saint Louis MO USA

4. Division of Liver Diseases; Department of Medicine; Mount Sinai School of Medicine; New York NY USA

5. Division of Hepatology; Northwestern University Feinberg School of Medicine; Chicago IL USA

6. Trio Health Analytics; La Jolla CA USA

7. Liver Care Network; Swedish Medical Center; Seattle WA USA

8. The Liver Center; Queen's Medical Center; Honolulu HI USA

9. Center for Liver Diseases; Department of Medicine; Inova Fairfax Hospital; Falls Church VA USA

Funder

Gilead Sciences

Publisher

Wiley

Subject

Pharmacology (medical),Gastroenterology,Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/apt.14204/fullpdf

Reference38 articles.

1. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence;Mohd Hanafiah;Hepatology,2013

2. Global epidemiology and genotype distribution of the hepatitis C virus infection;Gower;J Hepatol,2014

3. The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm;Razavi;J Viral Hepat,2014

4. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis;Meer;JAMA,2012

5. Sofosbuvir and ledipasvir improve patient-reported outcomes in patients co-infected with hepatitis C and human immunodeficiency virus;Younossi;J Viral Hepat,2016

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hepatitis C Elimination in Rwanda: Progress, Feasibility, and Economic Evaluation;Value in Health;2024-07

2. Real-life experience of ledipasvir and sofosbuvir for HCV infected Korean patients: a multicenter cohort study;The Korean Journal of Internal Medicine;2022-11-01

3. Real-world effectiveness and safety of sofosbuvir/velpatasvir and glecaprevir/pibrentasvir for genotype 6 chronic hepatitis C;Journal of the Formosan Medical Association;2022-11

4. BMS‐986263 in patients with advanced hepatic fibrosis: 36‐week results from a randomized, placebo‐controlled phase 2 trial;Hepatology;2021-12-13

5. Hepatitis C;Gastroenterology Clinics of North America;2020-06